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Abstract
Despite major advances in the treatment of asthma and the development of several asthma guidelines, people
still die of asthma currently. According to WHO estimates, approximately 250,000 people die prematurely each year from
asthma. Trends of asthma mortality rates vary very widely across countries, age and ethnic groups. Several risk factors
have been associated with asthma mortality, including a history of near-fatal asthma requiring intubation and mechanical
ventilation, hospitalization or emergency care visit for asthma in the past year, currently using or having recently stopped
using oral corticosteroids (a marker of event severity), not currently using inhaled corticosteroids, a history of psychiatric
disease or psychosocial problems, poor adherence with asthma medications and/or poor adherence with (or lack of) a
written asthma action plan, food allergy in a patient with asthma. Preventable factors have been identified in the majority
of asthma deaths. Inadequate education of patients on recognising risk and the appropriate action needed when asthma
control is poor, deficiencies in the accuracy and timing of asthma diagnosis, inadequate classification of severity and
treatment, seem to play a part in the majority of asthma deaths. Improvements in management, epitomized by the use
of guided self-management systems of care may be the key goals in reducing asthma mortality worldwide
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Background
Asthma is a serious global health problem affecting at
least 300 million people, with a high global burden of
disability [1–4]. Despite major advances in the treat-
ment of asthma and the development of several asthma
guidelines over the past decades, people still die of
asthma currently [1]. According to WHO estimates, ap-
proximately 250,000 people die prematurely each year
from asthma [3].
Main body
Trends of asthma mortality
Recorded asthma mortality rates vary very widely across
countries (http://dati.istat.it/) [5–23]. The estimates of
asthma deaths are affected by several factors. One of these
factors is precisely the correct estimation of mortality
from asthma. As the national mortality statistics are de-
rived from death certificates, inaccurate coding due to lack
of knowledge of the clinical history may lead to imprecise
estimation of mortality rates from asthma [24]. Then it
should be considered that international mortality statistics
for asthma are limited to those countries reporting a full
set of causes of death.
According to health statistics, asthma mortality has sig-
nificantly decreased worldwide over past decades. The
American Lung Association reported information, avail-
able from national and state-based surveys on the mortal-
ity due to asthma 1999–2009 [8, 9]. After a long period of
steady increase, evidence suggests that asthma mortality
and health care utilization rates continue to plateau and/
or decrease. The number of deaths due to asthma in 2009
was approximately 27 % lower than the number of deaths
seen in 1999 [9]. The number and rate of hospital dis-
charges have both decreased 24 % between 2003 and 2010
[10]. In Japan over 7000 patients died every year in the
1970s, while 1874 patients died of an asthma attack in
2012 [11, 12]. Asthma-related mortality in Europe has sig-
nificantly decreased, from 6287 deaths in 1985 to 1164 in
2012 (−80 %) [5].
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In Italy deaths from asthma have declined in recent
decades, passing from 1500 in 1995 to 429 in 2013 [6]
(http://dati.istat.it/).
Among children asthma mortality rates have been de-
clining since 2000 in countries where they have been
measured (Table 1).
The introduction of inhaled corticosteroids (ICS) in
the treatment of asthma, in the early 1970s, played a key
role in reducing asthma mortality. It’s widely recognized
that the widespread and progressive increase in the use
of ICS therapy over the past 20 to 30 years has de-
creased asthma mortality and morbidity [25], further,
ICS have been found to reduce asthma hospitalization
rates by as much as 80 % [26].
In contrast, several evidences show that inappropriate
use of beta agonist drugs may increase the risk of asthma
mortality. Short-acting-agonists (SABA) can induce toler-
ance and increase airway hyperresponsiveness [27, 28]. Ex-
cess use of SABA has also been found to increase the risk
of asthma death [29]. In the past, during the mid-to-late
1960s, the introduction of high dose isoprenaline inhalers
as an asthma reliever medication, which can have toxic
effects on the heart during acute asthma attacks, was asso-
ciated with an approximately 50 % increase in asthma
death rates among 5–34 year olds [14]. When these medi-
cations were withdrawn, the 1960s epidemic of asthma
deaths subsided. Successively, during the mid-1980s, an
increase of approximately 38 % in asthma death was asso-
ciated with the widespread use of fenoterol, another in-
haled asthma medication with potential cardiac toxicity
[14]. Recently, a metanalysis has been conducted of
asthma deaths in randomised controlled clinical trials that
compared salmeterol with a non-LABA comparator treat-
ment in asthma. Salmeterol monotherapy in asthma in-
creases the risk of asthma mortality and this risk is
reduced with concomitant ICS therapy [29].
Risk factors for asthma-related deaths
Several risk factors have been associated with asthma
mortality, including a history of near-fatal asthma requir-
ing intubation and mechanical ventilation, hospitalization
or emergency care visit for asthma in the past year, cur-
rently using or having recently stopped using oral cortico-
steroids (a marker of event severity), not currently using
inhaled corticosteroids, a history of psychiatric disease or
psychosocial problems, poor adherence with asthma med-
ications and/or poor adherence with (or lack of) a written
asthma action plan, food allergy in a patient with asthma
[1, 30–36].
Near-fatal asthma (NFA) and fatal asthma represent the
most severe clinical presentations of asthma. Near fatal
asthma (NFA) is described as acute asthma associated
with a respiratory arrest or arterial carbon dioxide tension
greater than 50 mmHg, with or without altered conscious-
ness requiring mechanical ventilation [4, 37–39]. In the
NFA the most important pathophysiological events that
lead to death are cardiac arrhythmias and asphyxia
followed by complications of invasive mechanical venti-
lation such as barotrauma and ventilator-associated
pneumonia. In a study of asthma patients admitted with
a near-fatal episode, two-thirds of subsequent severe at-
tacks or deaths occurred within 1 year of the previous
life-threatening admission [39].
A trigger of fatal and near fatal asthma was identified
in mould sensitivity [40–45]. Fungi are very common in
the environment and airborne spores are a normal com-
ponent of the outdoor air, so the respiratory exposure is
almost constant. Many different fungi have been impli-
cated in exacerbations of asthma, Alternaria spp., Cla-
dosporium spp. and Aspergillus fumigatus seem to be the
most important [40–47].
It was observed that the prevalence of sensitisation to
moulds (Alternaria alternate or Cladosporium herbarum,
or both) increased with increasing severity of asthma [40].
Sensitisation to moulds has been associated with in-
creased asthma severity and death, hospital admission and
intensive care admissions in adults and with increased
bronchial reactivity in children [40–48]. In a retrospective
study of 11 asthmatic patients who had a respiratory ar-
rest, 10 out of 11 were skin-test-positive for Alternaria al-
ternate [42].
Black et al. reported that twenty out of 37 patients
(54 %) admitted to the ICU for asthma had a positive
skin test for one or more fungal allergens [43]. Tar-
gonsky et al. reported that, during the pollen season,
mean concentrations of mould spores, but not of tree,
grass, or ragweed pollen, were significantly higher on the
days when there were deaths related to asthma than on
the days when no such deaths occurred [44].
It remains to be clarified the pathogenetic mecha-
nisms by which certain mould allergens produce more
severe airways disease than other common allergens.
A possible explanation is that fungi, compared to other al-
lergens, have the additional ability to actively germinate
and infect the host skin or attempt to colonise the respira-
tory tract [41]. It was suggested that mould allergens act-
ing in concert with other nonallergen proteins or toxins
produce an enhanced host response [41].
Several factors were identified as contributing factors
in asthma deaths [7–19, 49–65].
With the regard to age, Bellia et al. followed up 1233
ambulatory patients aged > 65 years with a diagnosis of
asthma or chronic non respiratory conditions and showed
Table 1 Trends in asthma mortality
In recent decades mortality from asthma has declined worldwide,
nevertheless the number of asthmatic patient who die still remains
very high.
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that asthma in the elderly was associated with higher mor-
tality rate, although this condition was not an independent
risk factor [16]. Differently, age was a significant predictor
of in-hospital mortality in asthma patients, however a
higher burden of underlying comorbidities in elderly pa-
tients could likely contribute to higher in-hospital mortal-
ity [13, 18]. Asthma hospitalization during the winter
months was also significantly predictive of increased in-
hospital mortality, probably because winter months
were associated with a concurrently higher prevalence
of respiratory viral infections, including influenza [13].
Elderly patients have a higher incidence of asthma ex-
acerbations and asthma-related deaths during the mid-
winter months [13, 19].
Among children, the International Study of Asthma and
Allergies in Childhood (ISAAC) found a significantly posi-
tive correlation between childhood asthma mortality and
the prevalence of more severe asthma symptoms in both
6–7 year olds (29 countries) and 13–14 year olds (38
countries) [48].
In a limited number of cases, exercise was described
as a trigger of fatal asthma attacks specially in children
and adolescents. In a preliminary investigation of asthma
mortality in US school between 1990 and 2003, 38
asthma deaths were reported [49]. Of the fatal asthma
attacks, 16 (42 %) occurred while the children were par-
ticipating in a physically active event [49].
In a report of asthma deaths during sports from 1993
until 2000, 61 cases were analyzed [50].
White males 10 to 20 years old were most at risk of
dying from asthma during sports. Sudden fatal asthma
exacerbations occured in both competitive and recre-
ational athletes. Athletes who played for either a profes-
sional or school team accounted for 57 % of the total
confirmed deaths. The rest (43 %) were people who
competed recreationally. 51 % of the victims died in the
middle of playing their sport [50].
In a 25-year follow-up study in a large cohort of asth-
matic patients, age, level of lung function, degree of
bronchodilator reversibility, peripheral blood eosinophil
count, and previous acute hospital contacts for asthma
at enrollment were identified as long-term risk factors
for subsequent death from asthma. After adjusting for
age and level of FEV1 % predicted, not allergic asthma
was associated with a higher risk of death from asthma
(RR, 1.9; 95 % CI, 1.1–3.2; p 5 .001) [15]. No significant
association was found between smoking habits or self-
reported symptom severity, and subsequent death from
asthma [15]. Lifetime tobacco consumption increases
the risk of death from asthma in a previous study [7].
Almind et al. previously showed an excess mortality
among male asthmatic smokers [51], whereas a Finnish
study found no association between mortality and smok-
ing among people with asthma [52].
Regarding to ethnic differences in asthma, there are only
a limited number of within-country investigations. Data
from the US have shown that African-Americans are at in-
creased risk of exacerbations, hospital attendances, near
death episodes, and mortality [17, 53–55]. This has led to
recent substantial investments ($23 m) to reduce asthma
disparities through the Patient-Centered Outcomes Re-
search Institute [56]. A previous systematic review and
meta-analysis investigating ethnic variations in asthma
outcomes in the UK found that South Asians (odds ratio
(OR) = 2.9; 95 % CI, 2.4–3.4) and Blacks (OR = 2.1; 95 %
CI, 1.8–2.5) were at substantially increased risk of hospital
admission from asthma when compared to White
European-origin populations [58].
Recently, a prospective study has examined the rela-
tionship between reproductive factors (parity and age at
first birth) and the risk of asthma death. There is a
significant protective effect of parity on the subse-
quent risk of death from asthma because risk of death
from asthma increased with increasing age at first
birth after adjusting for parity [58]. The finding of a
reduced risk of death from asthma associated with
higher parity is not in agreement with a previous
study conducted in Australia, which reported an in-
creased risk of later-onset asthma associated with
higher parity [59]. Jenkins et al. reported that the risk
of later-onset asthma among women who had no
asthma by age seven was associated with increased
parity. However, the risk of asthma decreased with in-
creasing age at first birth [59].
Psychological and social factors were also identified as
important contributing factors in asthma deaths [60, 61].
Bucknall et al., analyzing 95 deaths attributable to asthma,
found psychosocial problems in 58 % of cases; the com-
monest problems were depression and denial of symp-
toms or of the need of treatment [61].
In a small number of cases, thunderstorms in the pollen
season have been identified as triggers of severe asthma
exacerbations. The main hypotheses explaining associ-
ation between thunderstorms and asthma claim that thun-
derstorms may concentrate pollen grains at ground level
which may then release allergenic particles of respirable
size in the atmosphere after their rupture by osmotic
shock, which in turn may induce asthmatic reactions,
often severe [62–65].
Avoidable factors in asthma deaths
Over the past 50 years several studies have repeatedly
identified potentially preventable factors in the majority of
asthma deaths. Most of these factors deal with the man-
agement of asthma. Inadequate education of patients on
recognising risk and the appropriate action needed when
asthma control is poor, deficiencies in the accuracy and
timing of asthma diagnosis, inadequate classification of
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severity and treatment, seem to play a part in the majority
of asthma deaths [20, 21].
Recently a confidential enquiry in the United Kingdom,
the “National Review of Asthma Deaths” (NRAD), has re-
ported that deaths from asthma were avoidable in over
60 % of 195 cases of asthma deaths studied [20]. The
NRAD identified 195 cases of asthma deaths in the United
Kingdom during 2012–2013 [20]. Key findings from the
report include that nearly half died without seeking med-
ical assistance or before emergency medical care could be
provided, and the majority were not under specialist med-
ical supervision during the year prior to death [18, 19].
Only one-quarter had been provided with a personal
asthma action plan, acknowledged to improve asthma
care, and there was evidence of excessive prescribing of
short-acting reliever medication, under-prescribing of pre-
venter medication, and inappropriate prescribing of long-
acting beta-agonist bronchodilator inhalers as the sole
form of treatment. Overall asthma management (acute
and chronic) was satisfactory in only 31 % out of 195
people who died [20].
Conclusions
Death from asthma is a complex phenomenon and rep-
resents the “tip of the iceberg” with respect to the global
burden of asthma. Although asthma mortality rates have
declined in many high-income countries, continued sur-
veillance of asthma mortality rates is essential to moni-
tor progress in asthma care. Despite major advances in
the treatment, asthma still kills.
Preventable factors have been identified in the major-
ity of asthma deaths. Inadequate education of patients
on recognising risk and the appropriate action needed
when asthma control is poor, deficiencies in the accuracy
and timing of asthma diagnosis, inadequate classification
of severity and treatment, seem to play a part in the ma-
jority of asthma deaths.
Improvements in management, epitomized by the use
of guided self-management systems of care may be the
key goals in reducing asthma mortality worldwide.
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